If you have been reading about TH9507 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Plant resin is a viscoelastic solid polymer. When left in a container, it will flow slowly as a liquid to conform to the contours of its container. If struck with greater force, however, it will shatter as a solid.
In 2013, Essendon was investigated by the AFL and the Australian Sports Anti-Doping Authority (ASADA) over its 2012 player supplements program, specifically regarding the alleged use of the banned peptide Thymosin beta-4. On 27 August 2013, the AFL found the club guilty of bringing the game into disrepute for establishing a program that was "experimental, inappropriate and inadequately vetted". The club was fined A$2 million, stripped of early draft picks, and disqualified from the 2013 finals series. Senior coach James Hird was suspended for twelve months, and several executives, including chairman David Evans and CEO Ian Robson, resigned. Despite the AFL Anti-Doping Tribunal initially clearing the players in March 2015, the World Anti-Doping Agency (WADA) appealed the decision. On 12 January 2016, the Court of Arbitration for Sport overruled the AFL tribunal, finding 34 past and present players guilty of taking the banned substance. The players were suspended for the entire 2016 season. Forced to field a team composed heavily of VFL top-up players, Essendon claimed the wooden spoon in 2016 for the first time since 1933. Following the conclusion of the saga, Essendon made intermittent finals appearances, qualifying in 2017, 2019, and 2021 under coaches John Worsfold and Ben Rutten, but suffered elimination final defeats each time. The club has struggled to achieve significant post-season success, enduring a drought of finals victories that stretches back to 2004.
Linus Pauling Online a Pauling portal created by Oregon State University Libraries Crick, Francis, "The Impact of Linus Pauling on Molecular Biology" (transcribed from video at the 1995 Oregon State University symposium) The Ava Helen and Linus Pauling Papers at the Oregon State University Libraries The Pauling Catalogue Center for Oral History. "Linus C. Pauling". Science History Institute. Sturchio, Jeffrey L. (1987-04-06). Linus C. Pauling, Transcript of an Interview Conducted by Jeffrey L. Sturchio in Denver, Colorado on 6 April 1987 (PDF). Philadelphia, PA: Chemical Heritage Foundation. The Pauling Blog Linus Pauling (1901–1994) Berkeley Conversations With History interview Linus Pauling Centenary Exhibit Linus Pauling from The Dictionary of Unitarian and Universalist Biography Archived October 16, 2018, at the Wayback Machine "It's in the Blood! A Documentary History of Linus Pauling, Hemoglobin and Sickle Cell Anemia – Special Collections & Archives Research Center – Oregon State University". Oregon State University Library. Retrieved 2015-02-25. The Linus Pauling Institute at Oregon State University Publications of Pauling The Linus Pauling Papers – Profiles in Science, National Library of Medicine Linus Pauling Archived July 19, 2019, at the Wayback Machine Documentary produced by Oregon Public Broadcasting Oral history interview with Linus C. Pauling from Science History Institute Digital Collections
Sources: en.wikipedia.org
== Prognosis == As of March 2020, only 50 cases of CMRD have been documented in the medical literature. This small number speaks to the rarity of the disease as well as the lack of thorough research and documentation. As a result, the full course of the disease, life expectancy, and mortality are also poorly documented. Clinical manifestation of CMRD symptoms begin during infancy and early childhood but may go undetected due to the non-specific symptoms associated with the disease. Many of these symptoms can be attributed to malnutrition and nonspecific postnatal diarrhea, confounding early diagnosis. Careful regulation of diet and nutrition are required for management of CMRD since the disease results from the poor absorption of nutrients from food.
Platt, Harris & Tishkoff (2026) reconstruct likely patterns of interbreeding between Neanderthals and anatomically modern humans on the basis of the study of their X chromosomes, interpreted as indicating that their interbreeding predominantly involved Neanderthal men mating with anatomically modern women. Evidence from the study of Middle and Upper Paleolithic assemblages, indicating that overall anatomically modern human occupations can be distinguished from Neanderthal ones on the basis of tighter and more cohesive clusters of archaeological remains, is presented by Merino-Pelaz & Cobo-Sánchez (2026). Evidence of utility of the study of nonmetric traits at the enamel-dentine junction for distinguishing teeth of Neanderthals and modern humans is presented by Becam, Chevalier & Colard (2026). Kanis et al. (2026) identify amino acid changes in the growth hormone receptor of Neanderthals, including a change driving faster cell growth, and report evidence of more muscle mass in modern humans who inherited the gene encoding the Neanderthal growth hormone receptor through admixture. Zhang et al. (2026) present a new method for identification of evidence of archaic ancestry in modern human genomes, and report evidence of an introgression from an unknown archaic lineage into the ancestors of modern humans before their migration out of Africa. Evidence of effectiveness of the imputation in detection of Neanderthal and Denisovan ancestry in low-coverage ancient genomes is presented by Capodiferro et al. (2026) . Rao et al.
Cauliflower ear is an irreversible condition that occurs when the external portion of the ear is hit and develops a blood clot or other collection of fluid under the perichondrium. This separates the cartilage from the overlying perichondrium that supplies its nutrients, causing it to die and resulting in the formation of fibrous tissue in the overlying skin. As a result, the outer ear becomes permanently swollen and deformed, resembling a cauliflower, hence the name. The condition is common in sport wrestling, professional wrestling, boxing, and kickboxing, in martial arts such as Brazilian jiu-jitsu, judo, sumo, and mixed martial arts, and in full-contact sports such as rugby union and rugby league.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.